CoChat
Sign Up
Cited by 37

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Inhibition of Protein Ubiquitination by Paraquat and 1-Methyl-4-Phenylpyridinium Impairs Ubiquitin-Dependent Protein Degradation Pathways

Navarro-Yepes, Juliana, Anandhan, Annadurai, Bradley, Erin, Bohovych, Iryna, Yarabe, Bo, de Jong, Annemieke, Ovaa, Huib, Zhou, You, Khalimonchuk, Oleh, Quintanilla-Vega, Betzabet, Franco, Rodrigo·2016·Molecular Neurobiology
DOI 10.1007/s12035-015-9414-9PMC PMC4842169
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12035-015-9414-9

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 12 references

Research works printed but not linked: 169

  1. Tanaka K, Matsuda N (2014) Proteostasis and neurodegeneration: the roles of proteasomal degradation and autophagy. Biochim Biophys Acta 1843(1):197–204. doi: 10.1016/j.bbamcr.2013.03.012 · DOI
  2. Cook C, Stetler C, Petrucelli L (2012) Disruption of protein quality control in Parkinson’s disease. Cold Spring Harb Perspect Med 2(5):a009423. doi: 10.1101/cshperspect.a009423 · DOI
  3. Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H (2013) The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Mol Neurobiol 47(2):495–508. doi: 10.1007/s12035-012-8280-y · DOI
  4. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M et al (2002) p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 160(1):255–263. doi: 10.1016/S0002-9440(10)64369-6 · DOI · Paper page
  5. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y (1988) Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol 75(4):345–353 · DOI
  6. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95(11):6469–6473 · DOI · Paper page
  7. Gomez-Tortosa E, Newell K, Irizarry MC, Sanders JL, Hyman BT (2000) alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol 99(4):352–357 · DOI
  8. Choi AM, Ryter SW, Levine B (2013) Autophagy in human health and disease. N Engl J Med 368(7):651–662. doi: 10.1056/NEJMra1205406 · DOI · Paper page
  9. Navarro-Yepes J, Burns M, Anandhan A, Khalimonchuk O, del Razo LM, Quintanilla-Vega B, Pappa A, Panayiotidis MI et al (2014) Oxidative stress, redox signaling, and autophagy: cell death versus survival. Antioxid Redox Signal 21(1):66–85. doi: 10.1089/ars.2014.5837 · DOI
  10. Rogov V, Dotsch V, Johansen T, Kirkin V (2014) Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. Mol Cell 53(2):167–178. doi: 10.1016/j.molcel.2013.12.014 · DOI · Paper page
  11. Komatsu M, Kageyama S, Ichimura Y (2012) p62/SQSTM1/A170: physiology and pathology. Pharmacol Res 66(6):457–462. doi: 10.1016/j.phrs.2012.07.004 · DOI
  12. Watanabe Y, Tanaka M (2011) p62/SQSTM1 in autophagic clearance of a non-ubiquitylated substrate. J Cell Sci 124(Pt 16):2692–2701. doi: 10.1242/jcs.081232 · DOI
  13. Gal J, Strom AL, Kwinter DM, Kilty R, Zhang J, Shi P, Fu W, Wooten MW et al (2009) Sequestosome 1/p62 links familial ALS mutant SOD1 to LC3 via an ubiquitin-independent mechanism. J Neurochem 111(4):1062–1073. doi: 10.1111/j.1471-4159.2009.06388.x · DOI · Paper page
  14. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24(18):8055–8068. doi: 10.1128/MCB.24.18.8055-8068.2004 · DOI
  15. Babu JR, Geetha T, Wooten MW (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94(1):192–203. doi: 10.1111/j.1471-4159.2005.03181.x · DOI · Paper page
  16. Chondrogianni N, Petropoulos I, Grimm S, Georgila K, Catalgol B, Friguet B, Grune T, Gonos ES (2012) Protein damage, repair and proteolysis. Mol Asp Med. doi: 10.1016/j.mam.2012.09.001 · DOI
  17. Marques C, Pereira P, Taylor A, Liang JN, Reddy VN, Szweda LI, Shang F (2004) Ubiquitin-dependent lysosomal degradation of the HNE-modified proteins in lens epithelial cells. FASEB J 18(12):1424–1426. doi: 10.1096/fj.04-1743fje · DOI
  18. Klein C, Westenberger A (2012) Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2(1):a008888. doi: 10.1101/cshperspect.a008888 · DOI
  19. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS et al (2011) Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 119(6):866–872. doi: 10.1289/ehp.1002839 · DOI
  20. Kamel F (2013) Epidemiology. Paths from pesticides to Parkinson’s. Science 341(6147):722–723. doi: 10.1126/science.1243619 · DOI
  21. van der Mark M, Brouwer M, Kromhout H, Nijssen P, Huss A, Vermeulen R (2012) Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ Health Perspect 120(3):340–347. doi: 10.1289/ehp.1103881 · DOI
  22. Caudle WM, Guillot TS, Lazo CR, Miller GW (2012) Industrial toxicants and Parkinson’s disease. Neurotoxicology 33(2):178–188. doi: 10.1016/j.neuro.2012.01.010 · DOI
  23. Jang H, Boltz DA, Webster RG, Smeyne RJ (2009) Viral parkinsonism. Biochim Biophys Acta 1792(7):714–721. doi: 10.1016/j.bbadis.2008.08.001 · DOI
  24. Gorell JM, Rybicki BA, Cole Johnson C, Peterson EL (1999) Occupational metal exposures and the risk of Parkinson’s disease. Neuroepidemiology 18(6):303–308 · DOI
  25. Caneda-Ferron B, De Girolamo LA, Costa T, Beck KE, Layfield R, Billett EE (2008) Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson’s disease aetiology. J Neurochem 105(1):225–238. doi: 10.1111/j.1471-4159.2007.05130.x · DOI
  26. Yang W, Tiffany-Castiglioni E (2007) The bipyridyl herbicide paraquat induces proteasome dysfunction in human neuroblastoma SH-SY5Y cells. J Toxic Environ Health A 70(21):1849–1857. doi: 10.1080/15287390701459262 · DOI
  27. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL et al (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 102(9):3413–3418. doi: 10.1073/pnas.0409713102 · DOI
  28. Garcia-Garcia A, Anandhan A, Burns M, Chen H, Zhou Y, Franco R (2013) Impairment of Atg5-dependent autophagic flux promotes paraquat- and MPP+-induced apoptosis but not rotenone or 6-hydroxydopamine toxicity. Toxicol Sci 136(1):166–182. doi: 10.1093/toxsci/kft188 · DOI
  29. Wills J, Credle J, Oaks AW, Duka V, Lee JH, Jones J, Sidhu A (2012) Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways. PLoS One 7(1):e30745. doi: 10.1371/journal.pone.0030745 · DOI
  30. Janen SB, Chaachouay H, Richter-Landsberg C (2010) Autophagy is activated by proteasomal inhibition and involved in aggresome clearance in cultured astrocytes. Glia 58(14):1766–1774. doi: 10.1002/glia.21047 · DOI · Paper page
  31. Lei S, Zavala-Flores L, Garcia-Garcia A, Nandakumar R, Huang Y, Madayiputhiya N, Stanton RC, Dodds ED et al (2014) Alterations in energy/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate-dehydrogenase and the pentose phosphate pathway in paraquat toxicity. ACS Chem Biol. doi: 10.1021/cb400894a · DOI
  32. Scholz D, Poltl D, Genewsky A, Weng M, Waldmann T, Schildknecht S, Leist M (2011) Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 119(5):957–971. doi: 10.1111/j.1471-4159.2011.07255.x · DOI
  33. Rodriguez-Rocha H, Garcia-Garcia A, Zavala-Flores L, Li S, Madayiputhiya N, Franco R (2012) Glutaredoxin 1 protects dopaminergic cells by increased protein glutathionylation in experimental Parkinson’s disease. Antioxid Redox Signal. doi: 10.1089/ars.2011.4474 · DOI
  34. Seo YH, Carroll KS (2009) Profiling protein thiol oxidation in tumor cells using sulfenic acid-specific antibodies. Proc Natl Acad Sci U S A 106(38):16163–16168. doi: 10.1073/pnas.0903015106 · DOI
  35. Luo S, Wehr NB (2009) Protein carbonylation: avoiding pitfalls in the 2,4-dinitrophenylhydrazine assay. Redox Rep 14(4):159–166. doi: 10.1179/135100009X392601 · DOI
  36. Levine RL, Williams JA, Stadtman ER, Shacter E (1994) Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 233:346–357 · DOI
  37. Anandhan A, Rodriguez-Rocha H, Bohovych I, Griggs AM, Zavala-Flores L, Reyes-Reyes EM, Seravalli J, Stanciu LA et al (2014) Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. Neurobiol Dis. doi: 10.1016/j.nbd.2014.11.018 · DOI
  38. Myeku N, Metcalfe MJ, Huang Q, Figueiredo-Pereira M (2011) Assessment of proteasome impairment and accumulation/aggregation of ubiquitinated proteins in neuronal cultures. Methods Mol Biol 793:273–296. doi: 10.1007/978-1-61779-328-8_18 · DOI
  39. Rodriguez-Rocha H, Garcia-Garcia A, Pickett C, Li S, Jones J, Chen H, Webb B, Choi J et al (2013) Compartmentalized oxidative stress in dopaminergic cell death induced by pesticides and complex I inhibitors: distinct roles of superoxide anion and superoxide dismutases. Free Radic Biol Med 61C:370–383. doi: 10.1016/j.freeradbiomed.2013.04.021 · DOI
  40. Bence NF, Bennett EJ, Kopito RR (2005) Application and analysis of the GFPu family of ubiquitin-proteasome system reporters. Methods Enzymol 399:481–490. doi: 10.1016/S0076-6879(05)99033-2 · DOI
  41. Berkers CR, van Leeuwen FW, Groothuis TA, Peperzak V, van Tilburg EW, Borst J, Neefjes JJ, Ovaa H (2007) Profiling proteasome activity in tissue with fluorescent probes. Mol Pharm 4(5):739–748. doi: 10.1021/mp0700256 · DOI · Paper page
  42. de Jong A, Schuurman KG, Rodenko B, Ovaa H, Berkers CR (2012) Fluorescence-based proteasome activity profiling. Methods Mol Biol 803:183–204. doi: 10.1007/978-1-61779-364-6_13 · DOI
  43. Liu F, Hindupur J, Nguyen JL, Ruf KJ, Zhu J, Schieler JL, Bonham CC, Wood KV et al (2008) Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson’s disease-related insults. Free Radic Biol Med 45(3):242–255. doi: 10.1016/j.freeradbiomed.2008.03.022 · DOI
  44. Barde I, Salmon P, Trono D (2010) Production and titration of lentiviral vectors. Curr Protoc Neurosci Chapter 4:Unit 4 21. doi: 10.1002/0471142301.ns0421s53 · DOI
  45. Srivastava G, Dixit A, Yadav S, Patel DK, Prakash O, Singh MP (2012) Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb- and paraquat-induced parkinsonism in the mouse. Free Radic Biol Med 52(8):1294–1306. doi: 10.1016/j.freeradbiomed.2012.02.005 · DOI
  46. Goldman SM (2014) Environmental toxins and Parkinson’s disease. Annu Rev Pharmacol Toxicol 54:141–164. doi: 10.1146/annurev-pharmtox-011613-135937 · DOI
  47. Subramaniam SR, Chesselet MF (2013) Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol 106–107:17–32. doi: 10.1016/j.pneurobio.2013.04.004 · DOI
  48. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3(12):1301–1306. doi: 10.1038/81834 · DOI
  49. Sun F, Kanthasamy A, Anantharam V, Kanthasamy AG (2007) Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson’s disease. Pharmacol Ther 114(3):327–344. doi: 10.1016/j.pharmthera.2007.04.001 · DOI
  50. Corcoran LJ, Mitchison TJ, Liu Q (2004) A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr Biol 14(6):488–492. doi: 10.1016/j.cub.2004.03.003 · DOI
  51. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12(5):1393–1407 · DOI
  52. Stack JH, Whitney M, Rodems SM, Pollok BA (2000) A ubiquitin-based tagging system for controlled modulation of protein stability. Nat Biotechnol 18(12):1298–1302. doi: 10.1038/82422 · DOI
  53. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292(5521):1552–1555. doi: 10.1126/science.292.5521.1552 · DOI
  54. Li X, Zhao X, Fang Y, Jiang X, Duong T, Fan C, Huang CC, Kain SR (1998) Generation of destabilized green fluorescent protein as a transcription reporter. J Biol Chem 273(52):34970–34975 · DOI · Paper page
  55. Corish P, Tyler-Smith C (1999) Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng 12(12):1035–1040 · DOI
  56. Shamoto-Nagai M, Maruyama W, Kato Y, Isobe K, Tanaka M, Naoi M, Osawa T (2003) An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 74(4):589–597. doi: 10.1002/jnr.10777 · DOI
  57. Endo R, Saito T, Asada A, Kawahara H, Ohshima T, Hisanaga S (2009) Commitment of 1-methyl-4-phenylpyrinidinium ion-induced neuronal cell death by proteasome-mediated degradation of p35 cyclin-dependent kinase 5 activator. J Biol Chem 284(38):26029–26039. doi: 10.1074/jbc.M109.026443 · DOI
  58. Sawada H, Kohno R, Kihara T, Izumi Y, Sakka N, Ibi M, Nakanishi M, Nakamizo T et al (2004) Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J Biol Chem 279(11):10710–10719. doi: 10.1074/jbc.M308434200 · DOI
  59. Prasad K, Winnik B, Thiruchelvam MJ, Buckley B, Mirochnitchenko O, Richfield EK (2007) Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain. Environ Health Perspect 115(10):1448–1453. doi: 10.1289/ehp.9932 · DOI
  60. Seufert W, Jentsch S (1990) Ubiquitin-conjugating enzymes UBC4 and UBC5 mediate selective degradation of short-lived and abnormal proteins. EMBO J 9(2):543–550 · DOI
  61. Oh C, Park S, Lee EK, Yoo YJ (2013) Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention. Sci Rep 3:2623. doi: 10.1038/srep02623 · DOI
  62. Hanna J, Leggett DS, Finley D (2003) Ubiquitin depletion as a key mediator of toxicity by translational inhibitors. Mol Cell Biol 23(24):9251–9261 · DOI
  63. Shringarpure R, Grune T, Mehlhase J, Davies KJ (2003) Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 278(1):311–318. doi: 10.1074/jbc.M206279200 · DOI
  64. Kastle M, Reeg S, Rogowska-Wrzesinska A, Grune T (2012) Chaperones, but not oxidized proteins, are ubiquitinated after oxidative stress. Free Radic Biol Med 53(7):1468–1477. doi: 10.1016/j.freeradbiomed.2012.05.039 · DOI
  65. Long J, Garner TP, Pandya MJ, Craven CJ, Chen P, Shaw B, Williamson MP, Layfield R et al (2010) Dimerisation of the UBA domain of p62 inhibits ubiquitin binding and regulates NF-kappaB signalling. J Mol Biol 396(1):178–194. doi: 10.1016/j.jmb.2009.11.032 · DOI · Paper page
  66. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP et al (2007) Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 67(19):9472–9481. doi: 10.1158/0008-5472.CAN-07-0568 · DOI
  67. Bang Y, Kang BY, Choi HJ (2014) Preconditioning stimulus of proteasome inhibitor enhances aggresome formation and autophagy in differentiated SH-SY5Y cells. Neurosci Lett 566:263–268. doi: 10.1016/j.neulet.2014.02.056 · DOI
  68. Lan D, Wang W, Zhuang J, Zhao Z (2015) Proteasome inhibitor-induced autophagy in PC12 cells overexpressing A53T mutant alpha-synuclein. Mol Med Rep 11(3):1655–1660. doi: 10.3892/mmr.2014.3011 · DOI
  69. Lim J, Lee Y, Jung S, Youdim MB, Oh YJ (2014) Impaired autophagic flux is critically involved in drug-induced dopaminergic neuronal death. Parkinsonism Relat Disord 20(Suppl 1):S162–S166. doi: 10.1016/S1353-8020(13)70039-7 · DOI
  70. Myeku N, Figueiredo-Pereira ME (2011) Dynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy: association with sequestosome 1/p62. J Biol Chem 286(25):22426–22440. doi: 10.1074/jbc.M110.149252 · DOI · Paper page
  71. Kageyama S, Sou YS, Uemura T, Kametaka S, Saito T, Ishimura R, Kouno T, Bedford L et al (2014) Proteasome dysfunction activates autophagy and the Keap1-Nrf2 pathway. J Biol Chem 289(36):24944–24955. doi: 10.1074/jbc.M114.580357 · DOI
  72. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC (2009) Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 33(4):517–527. doi: 10.1016/j.molcel.2009.01.021 · DOI · Paper page
  73. Rubinsztein DC (2007) Autophagy induction rescues toxicity mediated by proteasome inhibition. Neuron 54(6):854–856. doi: 10.1016/j.neuron.2007.06.005 · DOI
  74. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, McLean PJ, Unni VK (2011) Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J Neurosci 31(41):14508–14520. doi: 10.1523/JNEUROSCI.1560-11.2011 · DOI
  75. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305(5688):1292–1295. doi: 10.1126/science.1101738 · DOI · Paper page
  76. Chorfa A, Betemps D, Morignat E, Lazizzera C, Hogeveen K, Andrieu T, Baron T (2013) Specific pesticide-dependent increases in alpha-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines. Toxicol Sci 133(2):289–297. doi: 10.1093/toxsci/kft076 · DOI
  77. Chorfa A, Lazizzera C, Betemps D, Morignat E, Dussurgey S, Andrieu T, Baron T (2014) A variety of pesticides trigger in vitro alpha-synuclein accumulation, a key event in Parkinson’s disease. Arch Toxicol. doi: 10.1007/s00204-014-1388-2 · DOI
  78. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 277(3):1641–1644. doi: 10.1074/jbc.C100560200 · DOI
  79. Mitra S, Chakrabarti N, Bhattacharyya A (2011) Differential regional expression patterns of alpha-synuclein, TNF-alpha, and IL-1beta; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. J Neuroinflammation 8:163. doi: 10.1186/1742-2094-8-163 · DOI
  80. Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P et al (2012) Alpha-synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287(19):15345–15364. doi: 10.1074/jbc.M111.318949 · DOI
  81. Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14(1):38–48. doi: 10.1038/nrn3406 · DOI
  82. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35(43):13709–13715. doi: 10.1021/bi961799n · DOI
  83. Khurana V, Lindquist S (2010) Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker’s yeast? Nat Rev Neurosci 11(6):436–449. doi: 10.1038/nrn2809 · DOI
  84. Trinh J, Farrer M (2013) Advances in the genetics of Parkinson disease. Nat Rev Neurol 9(8):445–454. doi: 10.1038/nrneurol.2013.132 · DOI
  85. Chung KK, Dawson VL, Dawson TM (2001) The role of the ubiquitin-proteasomal pathway in Parkinson’s disease and other neurodegenerative disorders. Trends Neurosci 24(11 Suppl):S7–S14 · DOI
  86. Clague MJ, Urbe S (2010) Ubiquitin: same molecule, different degradation pathways. Cell 143(5):682–685. doi: 10.1016/j.cell.2010.11.012 · DOI
  87. McNaught KS, Jenner P (2001) Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett 297(3):191–194 · DOI · Paper page
  88. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett 326(3):155–158 · DOI
  89. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol 179(1):38–46 · DOI · Paper page
  90. Martins-Branco D, Esteves AR, Santos D, Arduino DM, Swerdlow RH, Oliveira CR, Januario C, Cardoso SM (2012) Ubiquitin proteasome system in Parkinson’s disease: a keeper or a witness? Exp Neurol 238(2):89–99. doi: 10.1016/j.expneurol.2012.08.008 · DOI
  91. Wang XF, Li S, Chou AP, Bronstein JM (2006) Inhibitory effects of pesticides on proteasome activity: implication in Parkinson’s disease. Neurobiol Dis 23(1):198–205. doi: 10.1016/j.nbd.2006.02.012 · DOI
  92. Zeng BY, Iravani MM, Lin ST, Irifune M, Kuoppamaki M, Al-Barghouthy G, Smith L, Jackson MJ et al (2006) MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome. Eur J Neurosci 23(7):1766–1774. doi: 10.1111/j.1460-9568.2006.04718.x · DOI
  93. Kadoguchi N, Umeda M, Kato H, Araki T (2008) Proteasome inhibitor does not enhance MPTP neurotoxicity in mice. Cell Mol Neurobiol 28(7):971–979. doi: 10.1007/s10571-008-9271-4 · DOI
  94. Carvalho AN, Marques C, Rodrigues E, Henderson CJ, Wolf CR, Pereira P, Gama MJ (2013) Ubiquitin-proteasome system impairment and MPTP-induced oxidative stress in the brain of C57BL/6 wild-type and GSTP knockout mice. Mol Neurobiol 47(2):662–672. doi: 10.1007/s12035-012-8368-4 · DOI
  95. Xu Q, Farah M, Webster JM, Wojcikiewicz RJ (2004) Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor. Mol Cancer Ther 3(10):1263–1269 · DOI
  96. Ding Q, Dimayuga E, Markesbery WR, Keller JN (2006) Proteasome inhibition induces reversible impairments in protein synthesis. FASEB J 20(8):1055–1063. doi: 10.1096/fj.05-5495com · DOI
  97. Giordano S, Lee J, Darley-Usmar VM, Zhang J (2012) Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death. PLoS One 7(9):e44610. doi: 10.1371/journal.pone.0044610 · DOI
  98. Yacoubian TA, Slone SR, Harrington AJ, Hamamichi S, Schieltz JM, Caldwell KA, Caldwell GA, Standaert DG (2010) Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson’s disease. Cell Death Dis 1:e2. doi: 10.1038/cddis.2009.4 · DOI
  99. Song JX, Shaw PC, Wong NS, Sze CW, Yao XS, Tang CW, Tong Y, Zhang YB (2012) Chrysotoxine, a novel bibenzyl compound selectively antagonizes MPP(+), but not rotenone, neurotoxicity in dopaminergic SH-SY5Y cells. Neurosci Lett 521(1):76–81. doi: 10.1016/j.neulet.2012.05.063 · DOI
  100. Huang Y, Xu J, Liang M, Hong X, Suo H, Liu J, Yu M, Huang F (2013) RESP18 is involved in the cytotoxicity of dopaminergic neurotoxins in MN9D cells. Neurotox Res 24(2):164–175. doi: 10.1007/s12640-013-9375-6 · DOI
  101. Martins JB, Bastos Mde L, Carvalho F, Capela JP (2013) Differential effects of methyl-4-phenylpyridinium ion, rotenone, and paraquat on differentiated SH-SY5Y cells. J Toxicol 2013:347312. doi: 10.1155/2013/347312 · DOI
  102. Zhu M, Li WW, Lu CZ (2014) Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+. CNS Neurosci Ther 20(4):308–316. doi: 10.1111/cns.12217 · DOI
  103. Zhang X, Zhou J, Fernandes AF, Sparrow JR, Pereira P, Taylor A, Shang F (2008) The proteasome: a target of oxidative damage in cultured human retina pigment epithelial cells. Invest Ophthalmol Vis Sci 49(8):3622–3630. doi: 10.1167/iovs.07-1559 · DOI
  104. Jahngen-Hodge J, Obin MS, Gong X, Shang F, Nowell TR Jr, Gong J, Abasi H, Blumberg J et al (1997) Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem 272(45):28218–28226 · DOI
  105. Obin M, Shang F, Gong X, Handelman G, Blumberg J, Taylor A (1998) Redox regulation of ubiquitin-conjugating enzymes: mechanistic insights using the thiol-specific oxidant diamide. FASEB J 12(7):561–569 · DOI
  106. Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM et al (2004) Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A 101(29):10810–10814. doi: 10.1073/pnas.0404161101 · DOI
  107. Ishii T, Sakurai T, Usami H, Uchida K (2005) Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S proteasome. Biochemistry 44(42):13893–13901. doi: 10.1021/bi051336u · DOI
  108. Caballero M, Liton PB, Epstein DL, Gonzalez P (2003) Proteasome inhibition by chronic oxidative stress in human trabecular meshwork cells. Biochem Biophys Res Commun 308(2):346–352 · DOI
  109. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, Uchida K (1999) 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 274(34):23787–23793 · DOI
  110. Ding Q, Keller JN (2001) Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins. J Neurochem 77(4):1010–1017 · DOI
  111. Cotto-Rios XM, Bekes M, Chapman J, Ueberheide B, Huang TT (2012) Deubiquitinases as a signaling target of oxidative stress. Cell Rep 2(6):1475–1484. doi: 10.1016/j.celrep.2012.11.011 · DOI
  112. Lee JG, Baek K, Soetandyo N, Ye Y (2013) Reversible inactivation of deubiquitinases by reactive oxygen species in vitro and in cells. Nat Commun 4:1568. doi: 10.1038/ncomms2532 · DOI
  113. Shang F, Taylor A (2011) Ubiquitin-proteasome pathway and cellular responses to oxidative stress. Free Radic Biol Med 51(1):5–16. doi: 10.1016/j.freeradbiomed.2011.03.031 · DOI
  114. Shang F, Gong X, Taylor A (1997) Activity of ubiquitin-dependent pathway in response to oxidative stress. Ubiquitin-activating enzyme is transiently up-regulated. J Biol Chem 272(37):23086–23093 · DOI
  115. Monia BP, Ecker DJ, Crooke ST (1990) New perspectives on the structure and function of ubiquitin. Nat Biotechnol 8(3):209–215 · DOI
  116. Buttgereit F, Brand MD (1995) A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 312(Pt 1):163–167 · DOI
  117. Notter MF, Irwin I, Langston JW, Gash DM (1988) Neurotoxicity of MPTP and MPP+ in vitro: characterization using specific cell lines. Brain Res 456(2):254–262 · DOI
  118. Ling J, Soll D (2010) Severe oxidative stress induces protein mistranslation through impairment of an aminoacyl-tRNA synthetase editing site. Proc Natl Acad Sci U S A 107(9):4028–4033. doi: 10.1073/pnas.1000315107 · DOI
  119. Wei N, Shi Y, Truong LN, Fisch KM, Xu T, Gardiner E, Fu G, Hsu YS et al (2014) Oxidative stress diverts tRNA synthetase to nucleus for protection against DNA damage. Mol Cell 56(2):323–332. doi: 10.1016/j.molcel.2014.09.006 · DOI
  120. Tanaka M, Chock PB, Stadtman ER (2007) Oxidized messenger RNA induces translation errors. Proc Natl Acad Sci U S A 104(1):66–71. doi: 10.1073/pnas.0609737104 · DOI
  121. Shan X, Tashiro H, Lin CL (2003) The identification and characterization of oxidized RNAs in Alzheimer’s disease. J Neurosci 23(12):4913–4921 · DOI
  122. Shan X, Chang Y, Lin CL (2007) Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression. FASEB J 21(11):2753–2764. doi: 10.1096/fj.07-8200com · DOI
  123. Chang Y, Kong Q, Shan X, Tian G, Ilieva H, Cleveland DW, Rothstein JD, Borchelt DR et al (2008) Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS One 3(8):e2849. doi: 10.1371/journal.pone.0002849 · DOI
  124. Simms CL, Hudson BH, Mosior JW, Rangwala AS, Zaher HS (2014) An active role for the ribosome in determining the fate of oxidized mRNA. Cell Rep 9(4):1256–1264. doi: 10.1016/j.celrep.2014.10.042 · DOI
  125. Ding Q, Dimayuga E, Keller JN (2007) Oxidative stress alters neuronal RNA- and protein-synthesis: implications for neural viability. Free Radic Res 41(8):903–910. doi: 10.1080/10715760701416996 · DOI
  126. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J Neurochem 69(3):1326–1329 · DOI
  127. Saito Y, Hamakubo T, Yoshida Y, Ogawa Y, Hara Y, Fujimura H, Imai Y, Iwanari H et al (2009) Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients. Neurosci Lett 465(1):1–5. doi: 10.1016/j.neulet.2009.08.074 · DOI
  128. Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE, Gearing M, Levey AI et al (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281(16):10816–10824. doi: 10.1074/jbc.M509079200 · DOI
  129. Fang J, Nakamura T, Cho DH, Gu Z, Lipton SA (2007) S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson’s disease. Proc Natl Acad Sci U S A 104(47):18742–18747. doi: 10.1073/pnas.0705904104 · DOI
  130. Cho CS, Yoon HJ, Kim JY, Woo HA, Rhee SG (2014) Circadian rhythm of hyperoxidized peroxiredoxin II is determined by hemoglobin autoxidation and the 20S proteasome in red blood cells. Proc Natl Acad Sci U S A 111(33):12043–12048. doi: 10.1073/pnas.1401100111 · DOI
  131. Li X, Lu D, He F, Zhou H, Liu Q, Wang Y, Shao C, Gong Y (2011) Cullin 4B protein ubiquitin ligase targets peroxiredoxin III for degradation. J Biol Chem 286(37):32344–32354. doi: 10.1074/jbc.M111.249003 · DOI
  132. Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, Carter DM, Zhu PP et al (2003) L166P mutant DJ-1, causative for recessive Parkinson’s disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 278(38):36588–36595. doi: 10.1074/jbc.M304272200 · DOI
  133. Ravid T, Hochstrasser M (2008) Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 9(9):679–690. doi: 10.1038/nrm2468 · DOI
  134. Asher G, Reuven N, Shaul Y (2006) 20S proteasomes and protein degradation “by default”. BioEssays 28(8):844–849. doi: 10.1002/bies.20447 · DOI
  135. Sohal RS, Mockett RJ, Orr WC (2002) Mechanisms of aging: an appraisal of the oxidative stress hypothesis. Free Radic Biol Med 33(5):575–586 · DOI
  136. da Cunha FM, Demasi M, Kowaltowski AJ (2011) Aging and calorie restriction modulate yeast redox state, oxidized protein removal, and the ubiquitin-proteasome system. Free Radic Biol Med 51(3):664–670. doi: 10.1016/j.freeradbiomed.2011.05.035 · DOI
  137. Shang F, Gong X, Palmer HJ, Nowell TR Jr, Taylor A (1997) Age-related decline in ubiquitin conjugation in response to oxidative stress in the lens. Exp Eye Res 64(1):21–30. doi: 10.1006/exer.1996.0176 · DOI
  138. Yang F, Yang YP, Mao CJ, Liu L, Zheng HF, Hu LF, Liu CF (2013) Crosstalk between the proteasome system and autophagy in the clearance of alpha-synuclein. Acta Pharmacol Sin 34(5):674–680. doi: 10.1038/aps.2013.29 · DOI
  139. Petroi D, Popova B, Taheri-Talesh N, Irniger S, Shahpasandzadeh H, Zweckstetter M, Outeiro TF, Braus GH (2012) Aggregate clearance of alpha-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome. J Biol Chem 287(33):27567–27579. doi: 10.1074/jbc.M112.361865 · DOI · Paper page
  140. Korolchuk VI, Menzies FM, Rubinsztein DC (2010) Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 584(7):1393–1398. doi: 10.1016/j.febslet.2009.12.047 · DOI
  141. Bove J, Zhou C, Jackson-Lewis V, Taylor J, Chu Y, Rideout HJ, Wu DC, Kordower JH et al (2006) Proteasome inhibition and Parkinson’s disease modeling. Ann Neurol 60(2):260–264. doi: 10.1002/ana.20937 · DOI
  142. Kim YM, Jang WH, Quezado MM, Oh Y, Chung KC, Junn E, Mouradian MM (2011) Proteasome inhibition induces alpha-synuclein SUMOylation and aggregate formation. J Neurol Sci 307(1–2):157–161. doi: 10.1016/j.jns.2011.04.015 · DOI
  143. Kordower JH, Kanaan NM, Chu Y, Suresh Babu R, Stansell J 3rd, Terpstra BT, Sortwell CE, Steece-Collier K et al (2006) Failure of proteasome inhibitor administration to provide a model of Parkinson’s disease in rats and monkeys. Ann Neurol 60(2):264–268. doi: 10.1002/ana.20935 · DOI · Paper page
  144. Manning-Bog AB, Reaney SH, Chou VP, Johnston LC, McCormack AL, Johnston J, Langston JW, Di Monte DA (2006) Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 60(2):256–260. doi: 10.1002/ana.20938 · DOI
  145. Sun F, Anantharam V, Zhang D, Latchoumycandane C, Kanthasamy A, Kanthasamy AG (2006) Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 27(5):807–815. doi: 10.1016/j.neuro.2006.06.006 · DOI
  146. Xie W, Li X, Li C, Zhu W, Jankovic J, Le W (2010) Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease. J Neurochem 115(1):188–199. doi: 10.1111/j.1471-4159.2010.06914.x · DOI
  147. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K et al (2006) Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441(7095):885–889. doi: 10.1038/nature04724 · DOI · Paper page
  148. Kuusisto E, Salminen A, Alafuzoff I (2001) Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 12(10):2085–2090 · DOI
  149. Odagiri S, Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K (2012) Autophagic adapter protein NBR1 is localized in Lewy bodies and glial cytoplasmic inclusions and is involved in aggregate formation in alpha-synucleinopathy. Acta Neuropathol 124(2):173–186. doi: 10.1007/s00401-012-0975-7 · DOI
  150. Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K (2011) Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease. Neurobiol Dis 43(3):690–697. doi: 10.1016/j.nbd.2011.05.022 · DOI
  151. Watanabe Y, Tatebe H, Taguchi K, Endo Y, Tokuda T, Mizuno T, Nakagawa M, Tanaka M (2012) p62/SQSTM1-dependent autophagy of Lewy body-like alpha-synuclein inclusions. PLoS One 7(12):e52868. doi: 10.1371/journal.pone.0052868 · DOI
  152. Kuusisto E, Salminen A, Alafuzoff I (2002) Early accumulation of p62 in neurofibrillary tangles in Alzheimer’s disease: possible role in tangle formation. Neuropathol Appl Neurobiol 28(3):228–237 · DOI
  153. Nagaoka U, Kim K, Jana NR, Doi H, Maruyama M, Mitsui K, Oyama F, Nukina N (2004) Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem 91(1):57–68. doi: 10.1111/j.1471-4159.2004.02692.x · DOI
  154. Wooten MW, Geetha T, Seibenhener ML, Babu JR, Diaz-Meco MT, Moscat J (2005) The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J Biol Chem 280(42):35625–35629. doi: 10.1074/jbc.C500237200 · DOI
  155. Linares JF, Duran A, Yajima T, Pasparakis M, Moscat J, Diaz-Meco MT (2013) K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells. Mol Cell 51(3):283–296. doi: 10.1016/j.molcel.2013.06.020 · DOI
  156. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, Sun Z, White E et al (2010) A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 30(13):3275–3285. doi: 10.1128/MCB.00248-10 · DOI
  157. Tofaris GK, Kim HT, Hourez R, Jung JW, Kim KP, Goldberg AL (2011) Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A 108(41):17004–17009. doi: 10.1073/pnas.1109356108 · DOI · Paper page
  158. Zucchelli S, Codrich M, Marcuzzi F, Pinto M, Vilotti S, Biagioli M, Ferrer I, Gustincich S (2010) TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson’s disease brains. Hum Mol Genet 19(19):3759–3770. doi: 10.1093/hmg/ddq290 · DOI
  159. Mulherkar SA, Sharma J, Jana NR (2009) The ubiquitin ligase E6-AP promotes degradation of alpha-synuclein. J Neurochem 110(6):1955–1964. doi: 10.1111/j.1471-4159.2009.06293.x · DOI
  160. Lee FK, Wong AK, Lee YW, Wan OW, Chan HY, Chung KK (2009) The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson’s disease. J Neurochem 110(1):208–219. doi: 10.1111/j.1471-4159.2009.06124.x · DOI
  161. Lee JT, Wheeler TC, Li L, Chin LS (2008) Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum Mol Genet 17(6):906–917. doi: 10.1093/hmg/ddm363 · DOI
  162. Tofaris GK, Layfield R, Spillantini MG (2001) Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 509(1):22–26 · DOI · Paper page
  163. Meier F, Abeywardana T, Dhall A, Marotta NP, Varkey J, Langen R, Chatterjee C, Pratt MR (2012) Semisynthetic, site-specific ubiquitin modification of alpha-synuclein reveals differential effects on aggregation. J Am Chem Soc 134(12):5468–5471. doi: 10.1021/ja300094r · DOI
  164. Haj-Yahya M, Fauvet B, Herman-Bachinsky Y, Hejjaoui M, Bavikar SN, Karthikeyan SV, Ciechanover A, Lashuel HA et al (2013) Synthetic polyubiquitinated alpha-synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc Natl Acad Sci U S A 110(44):17726–17731. doi: 10.1073/pnas.1315654110 · DOI
  165. Liu C, Fei E, Jia N, Wang H, Tao R, Iwata A, Nukina N, Zhou J et al (2007) Assembly of lysine 63-linked ubiquitin conjugates by phosphorylated alpha-synuclein implies Lewy body biogenesis. J Biol Chem 282(19):14558–14566. doi: 10.1074/jbc.M700422200 · DOI
  166. Klucken J, Poehler AM, Ebrahimi-Fakhari D, Schneider J, Nuber S, Rockenstein E, Schlotzer-Schrehardt U, Hyman BT et al (2012) Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 8(5):754–766. doi: 10.4161/auto.19371 · DOI
  167. Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VM (2003) Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol 163(1):91–100 · DOI
  168. Dixon C, Mathias N, Zweig RM, Davis DA, Gross DS (2005) Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 170(1):47–59. doi: 10.1534/genetics.104.035493 · DOI
  169. Goel P, Manning JA, Kumar S (2015) NEDD4-2 (NEDD4L): the ubiquitin ligase for multiple membrane proteins. Gene 557(1):1–10. doi: 10.1016/j.gene.2014.11.051 · DOI

Cited by

Sorted by citations

See all 37

Metadata

Authors
Navarro-Yepes, J., Anandhan, A., Bradley, E., Bohovych, I., Yarabe, B., de Jong, A., Ovaa, H., Zhou, Y., Khalimonchuk, O., Quintanilla-Vega, B., & Franco, R.
Venue
Molecular Neurobiology
Publisher
Springer Science and Business Media LLC
Published
2015-09-26
Volume
53
Issue
8
Pages
5229-5251
ISSN
  • 0893-7648
  • 1559-1182
DOI
10.1007/s12035-015-9414-9
PMC
PMC4842169
Cited by
37
References
12
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review